Carson Allaria Wealth Management, Ltd. Biocryst Pharmaceuticals Inc Transaction History
Carson Allaria Wealth Management, Ltd.
- $169 Million
- Q3 2024
A detailed history of Carson Allaria Wealth Management, Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Carson Allaria Wealth Management, Ltd. holds 530 shares of BCRX stock, worth $3,990. This represents 0.0% of its overall portfolio holdings.
Number of Shares
530
Previous 230
130.43%
Holding current value
$3,990
Previous $1,000
300.0%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
278Shares Held
172MCall Options Held
625KPut Options Held
739K-
Vanguard Group Inc Valley Forge, PA20.3MShares$153 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$150 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.9MShares$89.3 Million1.36% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.09MShares$68.4 Million5.66% of portfolio
-
State Street Corp Boston, MA8.85MShares$66.6 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.4B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...